Company
LungLife AI Inc
LON:LLAI
LungLife AI Inc is a developer of clinical diagnostic solutions for lung cancer enhanced by AI. The company’s technology is comprised of rare-cell enrichment combined with blood-based biomarkers shown to be altered in lung cancer. The company employs machine learning to identify informative cells from blood and intends to build a deep, novel pool of lung cancer-related data for AI-enabled applications designed to improve test performance over time.
6 stories
LungLife AI moves to an early premium as it makes its debut on AIM
The group raised £17mln of new capital as part of the float